comparemela.com

Page 2 - Eric Nyberg News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Higher tech: Pittsburgh s Cognistx using AI to identify psychedelic drugs to treat depression, anxiety and PTSD

Higher tech: Pittsburgh’s Cognistx using AI to identify psychedelic drugs to treat depression, anxiety and PTSD It could be a trip worth taking the final frontier for psychiatry may actually be psychedelics. Maligned for decades as dangerous, illegal substances, psychedelic drugs such as psilocybin (“magic mushrooms”) LSD and mescaline are being studied as potential game-changers for alleviating treatment-resistant psychiatric problems, ranging from anxiety and depression to post-traumatic stress disorder. Cognistx, a Carnegie Mellon University spinoff based in Downtown Pittsburgh, is working with the Canadian biotech firm MagicMed to develop PsyAI, an artificial intelligence platform to streamline pharmaceutical research and accelerate the modernization of psychedelic medicine.

Cognistx Launches a Series of Virtual Events to Highlight the Use of AI for Business

Cognistx Launches a Series of Virtual Events to Highlight the Use of AI for Business Share Article Cognistx, a Pittsburgh-based tech firm, announced the launch of Cognistx Live, a series of talks on the practical use of AI for business. Cognistx Live kicks off with Real AI for Real Customers at 4:00 p.m. on Thursday, March 25. “Cognistx Live provides an in-depth look at how different industries use AI and how even the smallest company can unlock new business value by investing in artificial intelligence solutions,” Cognsitx CEO and Co-Founder Sanjay Chopra. PITTSBURGH (PRWEB) March 12, 2021 Cognistx (Cognistx.com), a tech firm that builds artificial intelligence (AI) business solutions, announced the launch of Cognistx Live, a series of talks on the practical use of AI for business.

MagicMed Industries announced another collaboration as the company begins to develop PsyAI

MagicMed Industries announced another collaboration as the company begins to develop PsyAI
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

MagicMed Industries Announces Collaboration with Artificial Intelligence Thought Leaders and the Launch of PsyAI™

MagicMed Industries Announces Collaboration with Artificial Intelligence Thought Leaders and the Launch of PsyAI™ USA - English Share this article MagicMed Industries Inc. (CSE: MGIC reserved) ( MagicMed or the Company ) announced today a collaboration among the Company, Dr. Suran Goonatilake and Dr. Eric Nyberg, renowned thought leaders in artificial intelligence ( AI ). Together the parties are building PsyAI TM, a tool designed to provide comprehensive, pharmaceutical design, manufacturing, pharmacology predictive and validating methodologies in an effort to modernize psychedelic medicine. The standard pharmaceutical candidate screening process is a consistent bottleneck in bringing standard pharmaceutical candidates to market and acts as a primary determinant of eventual clinical success or failure. This paradigm is particularly challenging in the psychedelics pharmaceutical sector, owing to a limited understanding of the mechanisms underlying observed clinical dat

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.